MK-2048: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
* Drug Class: [[Retroviral Integrase]] Inhibitor | * Drug Class: [[Retroviral Integrase]] Inhibitor | ||
* Expected FDA Approval: N/A (Currently in Phase III trials) | * Expected FDA Approval: N/A (Currently in Phase III trials) | ||
* Projected | * Projected Sales: N/A | ||
* Importance: It is a second generation [[Retroviral Integrase]] inhibitor expected to be the next effective HIV treatment to come to market. Clinical trials reveal that it is superior to [[Raltegravir]] with a nearly 4 times longer inhibition period. | * Importance: It is a second generation [[Retroviral Integrase]] inhibitor expected to be the next effective HIV treatment to come to market. Clinical trials reveal that it is superior to [[Raltegravir]] with a nearly 4 times longer inhibition period. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||
